TWI840312B - 一種中藥組合物及其用途 - Google Patents
一種中藥組合物及其用途 Download PDFInfo
- Publication number
- TWI840312B TWI840312B TW112143210A TW112143210A TWI840312B TW I840312 B TWI840312 B TW I840312B TW 112143210 A TW112143210 A TW 112143210A TW 112143210 A TW112143210 A TW 112143210A TW I840312 B TWI840312 B TW I840312B
- Authority
- TW
- Taiwan
- Prior art keywords
- parts
- chinese medicine
- breast cancer
- preparation
- medicine composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 20
- 239000003814 drug Substances 0.000 claims abstract description 79
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 40
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 40
- 208000024891 symptom Diseases 0.000 claims abstract description 32
- 241000405414 Rehmannia Species 0.000 claims abstract description 22
- 230000036506 anxiety Effects 0.000 claims abstract description 19
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 18
- 241001522129 Pinellia Species 0.000 claims abstract description 18
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 18
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 17
- 206010022437 insomnia Diseases 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims description 28
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 23
- 235000008397 ginger Nutrition 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 20
- 241001180873 Saposhnikovia divaricata Species 0.000 claims description 18
- 241000234314 Zingiber Species 0.000 claims description 18
- 241001369613 Stephania tetrandra Species 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 235000017803 cinnamon Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 241000723347 Cinnamomum Species 0.000 claims description 14
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 11
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 11
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 7
- 244000273928 Zingiber officinale Species 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000008113 selfheal Nutrition 0.000 claims description 5
- 230000003920 cognitive function Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 5
- 235000010254 Jasminum officinale Nutrition 0.000 claims 1
- 240000005385 Jasminum sambac Species 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 26
- 210000004185 liver Anatomy 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 17
- 206010016256 fatigue Diseases 0.000 abstract description 14
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 208000010877 cognitive disease Diseases 0.000 abstract description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 4
- 241001330502 Stephania Species 0.000 abstract description 4
- 235000008216 herbs Nutrition 0.000 abstract description 4
- 229940010454 licorice Drugs 0.000 abstract description 4
- 241001180876 Saposhnikovia Species 0.000 abstract description 3
- 230000001914 calming effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 13
- 235000010674 Prunella vulgaris Nutrition 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 10
- 238000010792 warming Methods 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 6
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 5
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000006999 cognitive decline Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010015967 Eye swelling Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 238000009261 endocrine therapy Methods 0.000 description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241001148495 Cibotium barometz Species 0.000 description 2
- 235000017788 Cydonia oblonga Nutrition 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 241001522232 Pinellia ternata Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- -1 SSRIs) Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本發明公開了一種中藥組合物,所述組合物有效成分原料的含有:生地黃、防己、夏枯草、桂枝、防風、炙甘草、炒梔子、法半夏、乾薑,具有益腎涼肝、養陰安神、通脈降逆,配合化療形神並調,達到減毒增效的作用。本發明的中藥組合物具有治療乳腺癌合併焦慮、抑鬱、失眠等心身症狀的作用。該組合物能夠明顯減輕和治癒乳腺癌患者焦慮、抑鬱、失眠、乏力、認知功能下降等症狀,效果顯著。
Description
本發明屬於中醫藥技術領域,尤其涉及一種治療乳腺癌合併焦慮、抑鬱、失眠、乏力、認知功能下降等心身症狀的中藥組合物及其製備方法和用途。
乳腺癌的診斷和治療對於患者而言一次是重大的心理應激(psychological stress,PS),心身問題時常貫穿於乳腺癌治療的各個階段,嚴重影響患者的生活品質,常見的心身問題如抑鬱、焦慮、失眠、認知功能下降等,都可能導致患者治療依從性降低、復發風險增加和生存率下降。化療是乳腺癌治療的重要組成部分,研究發現在乳腺癌化療期間,患者不僅容易出現睡眠障礙、記憶障礙等精神心理症狀,還會伴隨疲乏,噁心嘔吐和脫髮等軀體症狀,從而進一步促進焦慮、抑鬱的發生風險。乳腺癌患者常常合併焦慮、抑鬱狀態等情緒問題,並且在乳腺癌化療期間,由於化療常伴隨疲乏、噁心嘔吐、認知功能下降、脫髮等軀體症狀,從而進一步促進焦慮、抑鬱的發生發展。目前關於乳腺癌心身症狀的治療包括心理干預、生活方式調整和藥物治療。尚沒有針對乳腺癌化療患者的、規範化的藥物治療方法以綜合改善乳腺癌患者的焦慮、抑鬱、失眠等心身問題。
目前關於乳腺癌心身症狀的治療包括心理干預、生活方式調整和藥物治療:(1)心理干預在我國的患者接受度不高,需要花費較大的人力、物力;(2)生活方式的調整作用有限;(3)藥物治療常用5-羥色胺再攝取抑制劑(selective serotonin reuptake inhibitors, SSRIs)、去甲腎上腺素再攝取抑制劑(serotonin noradrenalin reuptake inhibitors, SNRIs)、苯二氮卓類藥物等,但部分SSRIs藥物是潛在的不可逆的 CYP2D6 抑制劑,可以阻止他莫昔芬代謝成活性化合物,因此存在降低乳腺癌內分泌治療藥物療效,且停藥後易出現症狀的反彈。
目前尚缺少針對乳腺癌化療患者的、規範化的藥物治療方法以綜合改善乳腺癌患者的焦慮、抑鬱、失眠等心身問題。
中醫藥是祖國醫學的瑰寶,歷來注重情志的調護,對疾病的診療也多從症狀著手,將“形與神俱”作為養生髎病的總則,注重整體觀與辨證論治的結合,與現代醫學的“生物-心理-社會醫療”模式,有異曲同工之處,因此中醫理論及治療方法有望為乳腺癌的心身健康的管理提供良好載體。一方面通過中醫內服外治、功法鍛煉等方法協助抗腫瘤治療,並減輕腫瘤本身或治療所帶來的軀體症狀,扶助正氣,增強體魄;另一方面,遵循《靈樞•師傳》:“告之以其敗,語之以其善,導之以其所便,開之以其所苦”的原則,在望聞問切中予以患者言語疏導,靈活選用調神養心之方藥,緩解患者焦慮抑鬱之情緒,從而達到外調形、內養神的作用。
研究發現太極拳鍛煉可以有效改善乳腺癌患者合併的抑鬱、焦慮、失眠等精神和軀體不適感,對乳腺癌術後合併抑鬱的患者應用逍遙散類方劑可改善抑鬱症狀,臨床研究報導可用吳茱萸粉調醋或自擬寧神膏、天灸膏進行穴位貼敷對乳腺癌失眠有明顯一定改善作用。
文獻“加味防己地黃湯治療乳腺癌內分泌治療後失眠的療效觀察”(《世界中西醫結合雜誌》2022年17卷5期)報導了在防己地黃湯的基礎上,增加了龍骨、牡蠣、法半夏、麩炒薏苡仁、百合、知母、炒酸棗仁、首烏藤、合歡皮和茯神,並發現加味防己地黃湯具有輔助內分泌治療、減輕患者失眠的效果。但該方組成清肝解鬱力量不足,未涉及對焦慮、抑鬱應激症狀的改善,且主要針對內分泌治療期患者,而失眠、焦慮、抑鬱、乏力、認知功能下降症狀從化療階段就會出現,並長期伴隨。
因此中醫治療思路需調整,就乳腺癌合併心身症狀,特別是焦慮、抑鬱、失眠、乏力、認知功能下降等症狀的治療方式探尋新的治療方法。
通過長期臨床實踐發現,化療藥物屬大熱之邪,進入人體殺傷癌細胞的同時也攻擊機體正常組織,有形之體受損,反過來進一步擾亂以其為載體的人神,導致形神俱損。臨床上化療病人常出現肝腎陰虛,痰熱瘀阻的表現。癌毒與化療同屬熱毒之邪,兩邪相爭於體內,必耗氣傷津,加上患者情志長期疏泄不暢,內外合邪化火,劫奪肝腎真陰,以致陰陽失衡,水火失濟,虛火上炎,循脈入心,擾亂心神,故患者易見焦慮抑鬱、五心煩熱、心悸不安、形體消瘦、頭暈耳鳴。肝鬱失疏,橫逆犯脾,脾失健運則易痰濁內生,胃失和降而其氣上逆,故見噁心嘔吐,食欲不振,脘腹脹滿。津血不足,鬱熱煎熬氣血,必有瘀血內生,故化療患者常見舌質暗紅少津有瘀斑,邊有齒痕,少苔或無苔,脈細數。
為了克服上述現有技術中存在的不足,發明人創立了本發明——“防夏地黃方”,以益腎涼肝、養陰安神、通脈降逆,配合化療形神並調,達到減毒增效的作用。本方在防已地黃湯的基礎上加減化裁而來。防己地黃湯出自《金匱要略·中風曆節病脈證並治第五》,在臨床中常常作為經方治療神志病的專方。經過大量臨床試驗研究,最終確定了組方含有生地黃、防己、夏枯草、桂枝、防風、炙甘草、炒梔子、法半夏、乾薑。
方中重用生地黃為君,經方大家胡希恕先生認為生地黃是“強壯性的祛瘀藥”,在經方百合地黃湯、炙甘草湯、膠艾湯、腎氣丸、薯蕷丸、黃土湯、大黃蟄蟲丸中也有應用,是仲景治療陰津不足、血分有熱、血脈不通的重要用藥。《神農本草經》中載其“主折跌絕筋,傷中,逐血痹,填骨髓,長肌肉”,故生地黃在本方中還具有補中填髓,改善化療後骨髓抑制的功用;同時因質潤,可兼顧潤腸通便改善化療所致便秘。
防己、夏枯草為臣,助君藥清熱涼肝。《神農本草經疏》載防己可治“熱氣諸癇”,與治療神志病相通;配伍法半夏可加強燥濕化痰散結之用。夏枯草是清肝火、散鬱結的要藥,歷代醫家認為夏枯草還具有和陽養陰、補養厥陰血脈之功,退寒熱無論虛實皆可用。
佐藥之中,防風屬芳香辛散之風藥,可開通鬱閉,發散鬱熱,“搜肝氣”而不傷陰(《湯藥本草》),合生地涵木、桂枝平肝,調達肝氣。桂枝能溫通血脈,合生地交通心腎,與甘草相合則可安神定悸,對神志異常大有裨益。梔子清瀉三焦火邪,加強本方解鬱除煩之功,最新研究表明梔子的主要有效成分槲皮苷可以通過快速抗炎作用改善神經突觸可塑性而快速起效抗抑鬱。乾薑與半夏配伍乃《金匱要略》半夏乾薑散,加強溫中化飲止嘔的力量,適用於化療期間出現的幹嘔或吐涎沫等本虛標實的患者,還可防止生地寒涼滋膩礙胃之弊。法半夏同時具有辛開散結消胸脘痞悶。
炙甘草調和諸藥為使藥。
生地黃:性味甘,苦,寒。歸心、肝經,清熱涼血而除煩止血;入腎經,滋陰生津、潤滑大腸而止咳、通便。長於清熱涼血、熱盛傷津及血熱出血多用。
防己:性苦,寒。歸膀胱、肺經。防己苦泄降,辛行散,寒能清,入膀胱、腎、脾經。祛風濕止痛力強,並能清熱,治濕熱痹痛尤佳;清熱利水,除下焦濕熱,治濕熱瘡疹、腳氣浮腫、水腫間熱可投。
夏枯草:性辛、苦,寒。歸肝、膽經。清熱瀉火,明目,散結消腫。主治目赤腫痛、頭痛眩暈、目珠夜痛;苦寒主入肝經,善瀉肝火以明目;用治肝火上炎,目赤腫痛;瘰鬁、癭瘤。本品味辛能散結,苦寒能泄熱,用以治肝鬱化火,痰火凝聚之瘰鬁;既能清熱去肝火,又能散結消腫,可治乳癰腫痛。
桂枝:性味辛、甘,溫。歸心、肺、膀胱經。辛散溫通,甘溫助陽,溫通流暢,濕助一身之陽氣,流暢一身之血脈。入肺、膀胱經,善散風寒而解在表之風寒或風邪。入心經與血分,善溫通助陽、散寒邪、通血脈、暢胸陽、溫化水濕、止疼痛。具有發汗解肌,溫通經脈,助陽化氣,平沖降氣的功效。
防風:性味辛、甘,微溫。防風辛微溫發散,甘緩不峻,生用、炒炭性能有別。生用辛散甘緩,入膀胱、脾經,散外風、勝濕邪而發表止痛;入肝經,祛內風而止痙。治風通用藥,散外風、息內風皆宜,治風寒、風熱及表證夾濕皆可,風寒濕三邪客體用之最宜。炒炭,澀多散少,斂兼升散,入脾、肝經而長於止血、止泄,治崩漏下血及泄瀉宜用。
炙甘草:藥性甘,平。歸心、肺、脾、胃經。具有補脾和胃,益氣複脈的功效。用於脾胃虛弱,倦怠乏力,心動悸,脈結代。
炒梔子:果實具有瀉火除煩,清熱利尿,涼血解毒的效果,用於熱病心煩,黃疸尿赤,血淋澀痛,血熱吐衄,目赤腫痛,火毒瘡瘍;外治扭挫傷痛。其根具有瀉火解毒,清熱利濕,涼血散瘀的功效,用於傳染性肝炎,跌打損傷,風火牙痛。
法半夏:性辛,溫。歸脾、胃、肺經。具有燥濕化痰的功效。主治痰多咳喘,痰飲眩悸,風痰眩暈,痰厥頭痛。
乾薑:性辛,熱。歸脾、胃、腎、心、肺經。姜辛熱溫散,入脾、胃經,既祛脾胃寒邪,又助脾陽氣,為溫中祛寒之要藥,無論實寒、虛寒皆宜。入心經,能回陽通脈,常輔助附子以回陽救逆,治亡陽欲脫。入肺經,能溫肺化飲,治寒飲咳喘常投。有溫中散寒,回陽通脈,溫肺化飲的功效。
經長時間的研究證明,本發明在防己地黃湯的基礎上進行藥味增加獲得的最終處方是最優選擇。本發明加方所選擇的各種藥材相互配伍組合,組合後的治療效果比使用其他藥味的效果提高很多。
本發明的一方面,提供一種治療乳腺癌合併焦慮、抑鬱、失眠、乏力或認知功能下降等心身症狀的中藥組合物,所述的中藥組合物所用原料藥為:生地黃、防己、夏枯草、桂枝、防風、炙甘草、炒梔子、法半夏、乾薑,優選其重量比為:
生地黃 | 15-60 | 份 | ,優選 | 24-36 | 份 |
防己 | 6-12 | 份 | ,優選 | 8-12 | 份 |
夏枯草 | 10-20 | 份 | ,優選 | 12-18 | 份 |
桂枝 | 3-12 | 份 | ,優選 | 5-7 | 份 |
防風 | 6-12 | 份 | ,優選 | 6-8 | 份 |
炙甘草 | 3-9 | 份 | ,優選 | 5-7 | 份 |
炒梔子 | 6-12 | 份 | ,優選 | 8-12 | 份 |
法半夏 | 6-12 | 份 | ,優選 | 7-11 | 份 |
乾薑 | 6-12 | 份 | ,優選 | 7-11 | 份 |
作為本發明優選的技術方案,各原料藥的重量用比為:
生地黃30份、防己10份、夏枯草15份、桂枝6份、防風10份、炙甘草6份、炒梔子10份、法半夏9份、乾薑9份;或
生地黃60份、防己12份、夏枯草20份、桂枝12份、防風12份、炙甘草9份、炒梔子12份、法半夏12份、乾薑12份;或
生地黃15份、防己6份、夏枯草10份、桂枝3份、防風6份、炙甘草3份、炒梔子6份、法半夏6份、乾薑6份。
在使用過程中,每天用藥可按照以下處方使用:生地黃15-60g,防己6-12g、夏枯草10-20g、桂枝3-12g、防風6-12g、炙甘草3-9克,炒梔子6-12g,法半夏6-12g,乾薑6-12g。可以根據患者體重、身體狀態等條件,在該用量範圍內進行適當調整。例如:生地黃60g、防己12g、夏枯草20g、桂枝12g、防風12g、炙甘草9g、炒梔子12g、法半夏12g、乾薑12g;或,生地黃15g、防己6g、夏枯草10g、桂枝3g、防風6g、炙甘草3g、炒梔子6g、法半夏6g、乾薑6g的用量用藥。
在臨床使用中,生地黃30g,防己10g、夏枯草15g、桂枝6g、防風10g、炙甘草6克,炒梔子10g,法半夏9g,乾薑9g的組方使用最為普遍。
本領域中藥的常規煎煮方法優選將藥物一起混合後直接加水煎煮,煎煮過程按照通常中藥湯劑煎煮方法進行。當然也可以根據具體條件,將藥物分別煎煮後進行合併。為了減少服用藥液體積,也可以將煎煮得到的水煎液進行一定程度的濃縮。
當藥物量比較大時,例如在工業化生產過程中,將藥味加水浸泡,侵泡後的藥味加水煎煮,煎煮三次,每次1-2小時;煎液濾過藥渣,合併。為獲得濃縮液,濾液可進行濃縮。
本發明的中藥組合物可以採用中藥製劑的常規方法製備成中藥內服製劑,例如將原料藥物進行水煎,或用醇水混合物提取,然後濃縮乾燥水煎液或提取液,製成乾燥浸膏粉,將浸膏粉與藥物添加適當的輔料,用本領域技術人員常規的製藥方法,製備成中藥內服製劑,包括片劑、顆粒劑、口服液、合劑等。也可以按照藥材配比配置成一份中藥材組合,提供給患者自己煎煮成湯劑。
也可以在上述中藥的基礎上加入其它藥物,組合成多種組方,發揮不同程度的功效。
在本發明的另一方面,提供一種所述的中藥組合物的製備方法,包括如下步驟:
全部藥味加水煎煮2次,第1次60min,第2次30min,濾過藥渣,合併兩次煎煮所得藥液,攪拌均勻,即得。可按照要服用的次數,將其均分為相應的份數,例如提供一天的藥量,一天分兩次服用,可以將其均分為二。
在本發明的一個優選實施方案中,其服用方法包括:將所述組分混合後進行水煎,每天1劑,分兩次服用。進一步優選的,其服用方法還包括:每個化療週期第3天開始服用,連續用藥14d,兩個化療週期為一個療程。更進一步優選的,其服用方法還包括:每個化療週期第8天開始服用,連續用藥14d,兩個化療週期為一個療程。
在本發明的另一方面,提供上述中藥組合物在製備治療乳腺癌合併心身症狀的藥物中的應用,所述乳腺癌合併心身症狀包括焦慮、抑鬱、失眠、乏力、認知功能下降等症狀。
本發明的有益效果是:
1、本發明的中藥藥物組成具有滋水涵木、散熱除煩、化瘀降逆的作用。
2、配合化療可以起到形神並調,同時改善焦慮、抑鬱、失眠、疲乏等症狀。
以下通過具體實施方式的描述對本發明作進一步說明,但這並非是對本發明的限制,本領域技術人員根據本發明的基本思想,可以做出各種修改或改進,但是只要不脫離本發明的基本思想,均在本發明的範圍之內。
實施例1
處方
生地黃60g,防己12g、夏枯草20g、桂枝12g、防風12g、炙甘草9克,炒梔子12g,法半夏12g,乾薑12g。
制法
全部藥味加水煎煮2次,第1次60min,第2次30min ,濾過藥渣,合併兩次煎煮所得藥液,攪拌均勻,均分為二,即得。
實施例 2
處方
生地黃15g,防己6g、夏枯草10g、桂枝3g、防風6g、炙甘草3克,炒梔子6g,法半夏6g,乾薑6g。
制法
全部藥味加水煎煮2次,第1次60min,第2次30min ,濾過藥渣,合併兩次煎煮所得藥液,攪拌均勻,均分為二,即得。
實施例 3
處方
生地黃30g,防己10g、夏枯草15g、桂枝6g、防風10g、炙甘草6克,炒梔子10g,法半夏9g,乾薑9g。
制法
全部藥味加水煎煮2次,第1次60min,第2次30min ,濾過藥渣,合併兩次煎煮所得藥液,攪拌均勻,均分為二,即得。
實施例 4
處方
地黃333.3g、夏枯草166.7g、防己111.1g、桂枝66.7g、防風111.1g、乾薑100.0g、法半夏100.0g、炒梔子111.1g、炙甘草66.7克。
制法
以上九味,加水浸泡30分鐘,煎煮三次,每次1.5小時,煎液濾過,濾液合併減壓濃縮,加入適量抑菌劑水溶液,加水攪勻,濾過,藥用聚丙烯瓶灌裝分裝,藥用聚酯/鋁/聚丙烯封口墊片熱封,105 ℃滅菌30 min,即得。
試驗例
1 資料與方法
選取就診于北京中醫藥大學第三附屬醫院乳腺科、北京中醫藥大學廈門醫院胸外乳腺科門診或病房的乳腺癌患者。
(1)診斷標準
西醫診斷標準:乳腺癌診斷標準參照《中國抗癌協會乳腺癌診治指南與規範》(2021年版);分期標準參照美國癌症聯合委員會(AJCC)乳腺癌TNM 分期標準(第八版,2017)。
中醫證候診斷標準:參考 《中藥新藥臨床研究指導原則》和《早期乳腺癌中醫辨證內治專家共識》,制定肝腎陰虛,瘀熱擾神證中醫證候診斷如下:
主症:①精神抑鬱或急躁②頭暈耳鳴③腰膝酸軟④五心煩熱,潮熱。
次症:①失眠②健忘③脫髮④足跟疼痛⑤體倦乏力⑥爪甲變黑或不澤,形體消瘦⑦口咽乾燥⑧盜汗。
舌脈:舌質暗紅少津有瘀斑,少苔或無苔、脈細數。
證型確定:具備主症2項(第1項必備)加次症2項,參考舌脈即可診斷。
(2)納入標準
① 年齡18-70歲女性;
② 經病理學診斷的、臨床分期為 I~III期的乳腺癌術後患者;
③ 正在行術後輔助化療;
④ ECOG評分 0-2;
⑤ 符合肝腎陰虛,瘀熱擾神的中醫證候診斷;
⑥ 簽署知情同意,自願參加本研究。
(3)排除標準
① 合併嚴重的心、腦血管、肝、腎、造血系統疾病或其他惡性腫瘤者;
② 對研究藥物過敏者;
③ 不知曉乳腺癌診斷者;
④ 合併嚴重精神障礙病史;
⑤ 近三個月內接受過心理治療或心理干預;
⑥ 妊娠期、哺乳期婦女。
(4)干預方案
干預藥物:在規範化療方案的基礎上,給予實施例1至3製備的中藥複方防夏地黃方,其中約80%患者使用實施例3處方。針對患者的特點,部分患者使用的是實施例1、2的處方。
用藥方法:每日1劑,分早、晚溫服。於每次化療後第3天開始服用,連服14天。共觀察2個化療週期。
安全性檢查與不良反應處理:每週期化療均行三大常規、肝腎功能、腫瘤標誌物、心電圖、雙乳及腋下B 超。化療期間出現骨髓抑制的患者給予皮下注射吉粒芬(重組人粒細胞集落刺激因數)等對症處理,出現噁心嘔吐等胃腸道反應予昂丹司瓊對症處理,出現肝損傷者根據損傷程度予對症保肝治療。
(5)觀察指標
一般情況
姓名、性別、年齡、聯繫方式、既往史等。入組時記錄。
疾病資料
診斷方式、原發部位、腫瘤大小、腋窩淋巴結轉移、病理類型、分子分型、組織分化程度、Ki-67表達水準、TNM分期和新輔助化療方案。入組時記錄。
主要觀察指標
(1)廣泛性焦慮量表(Generalized Anxiety Disor-der Scale,GAD-7)。
(2)PHQ-9量表:病人健康問卷抑鬱量表(Patient Health Questionnaire Depression Module,PHQ-9)。
次要觀察指標
(1)匹茨堡睡眠品質指數(PSQI)。
(2)中文版Piper疲乏修訂量表(RPFS-CV)。
以上主要及次要項指標均于入組時、治療結束後進行評估。
安全性指標
每個化療週期均檢測血、尿便常規、肝腎功能、心電圖,記錄治療期間的不良反應。
(6)統計學方法
採用SPSS26.0軟體進行資料統計分析:計量資料以均數±標準差表示。計量資料組內治療前後資料滿足正態分佈時,釆用配對檢驗,不滿足時採用兩相關樣本非參數檢驗;統計採用雙側差異性檢驗,P小於0.05時認為具有統計學意義。
(7)結果
各指標治療前後變化詳見下表1和表2。
受試者在臨床研究期間均未見原發腫瘤病情進展,無嚴重不良事件的出現。
表1 治療前後GAD-7、PHQ-9、PSQI得分對比
治療前 | 治療後 | P | |||||
GAD-7(n=35) | 8.53±4.04 | 5.68±2.74 | <0.01 | ||||
PHQ-9(n=35) | 7.82±4.38 | 5.36±3.59 | <0.05 | ||||
PSQI(n=35) | 9.53±4.04 | 5.68±2.74 | <0.01 | ||||
表2 治療前後RPFS-CV對比
治療前 | 治療後 | P | |||||
總分(n=35) | 6.35±1.04 | 3.78±1.64 | <0.05 | ||||
行為維度(n=35) | 7.82±1.74 | 4.05±1.32 | <0.05 | ||||
情感維度(n=35) | 8.53±2.08 | 4.12±1.51 | <0.05 | ||||
感覺維度(n=35) | 7.57±1.56 | 3.66±1.01 | <0.01 | ||||
認知維度(n=35) | 5.35±1.51 | 4.33±1.25 | <0.05 | ||||
經過本發明防夏地黃方治療後,乳腺癌化療患者的焦慮、抑鬱得分及睡眠指數均較治療前明顯下降,差異具有統計學意義;疲乏方面,經中藥干預後,患者的疲乏得分從各個維度均有顯著改善,差異具有統計學意義。
最後應說明的是:以上所述僅為本發明的優選實施例而已,並不用於限制本發明,儘管參照前述實施例對本發明進行了詳細的說明,對於本領域的技術人員來說,其依然可以對前述各實施例所記載的技術方案進行修改,或者對其中部分技術特徵進行等同替換。凡在本發明的精神和原則之內,所作的任何修改、等同替換、改進等,均應包含在本發明的保護範圍之內。
Claims (11)
- 一種治療乳腺癌合併心身症狀的中藥組合物,其特徵在於,所述的中藥組合物所用原料藥為:生地黃、防己、夏枯草、桂枝、防風、炙甘草、炒梔子、法半夏、乾薑,所用各原料藥的重量份為:生地黃 15-60份;防己 6-12份;夏枯草 10-20份;桂枝 3-12份;防風 6-12份;炙甘草 3-9份;炒梔子 6-12份;法半夏 6-12份;以及乾薑 6-12份。
- 根據請求項1所述治療乳腺癌合併心身症狀的中藥組合物,其中,所述乳腺癌合併心身症狀為焦慮、抑鬱、失眠、乏力或認知功能下降。
- 根據請求項1所述治療乳腺癌合併心身症狀的中藥組合物,其中,所用各原料藥的重量份為:生地黃 24-36份;防己 8-12份;夏枯草 12-18份; 桂枝 5-7份;防風 6-8份;炙甘草 5-7份;炒梔子 8-12份;法半夏 7-11份;以及乾薑 7-11份。
- 根據請求項1所述治療乳腺癌合併心身症狀的中藥組合物,其中,所述各原料藥的重量份為:生地黃30份、防己10份、夏枯草15份、桂枝6份、防風10份、炙甘草6份、炒梔子10份、法半夏9份、乾薑9份;或生地黃60份、防己12份、夏枯草20份、桂枝12份、防風12份、炙甘草9份、炒梔子12份、法半夏12份、乾薑12份;或生地黃15份、防己6份、夏枯草10份、桂枝3份、防風6份、炙甘草3份、炒梔子6份、法半夏6份、乾薑6份。
- 用於治療乳腺癌合併心身症狀的中藥組合物的製備方法,其特徵在於包括以下步驟:根據請求項1-4任一項的原料藥及其重量份投料;將全部藥味加水煎煮,濾過藥渣,合併煎煮所得藥液,攪拌均勻。
- 根據請求項5所述的製備方法,其中,所述煎煮過程為煎煮2至4次。
- 根據請求項5所述的製備方法,其中: 將全部藥味加水煎煮2次,第1次60min,第2次30min,濾過藥渣,合併兩次煎煮所得藥液,攪拌均勻。
- 根據請求項5-7任意一項所述製備方法,其中,還包括以下步驟:將所獲得的藥液進一步製備成口服製劑。
- 一種治療乳腺癌合併心身症狀的中藥製劑,其特徵在於該中藥製劑含有請求項1至4任意一項的中藥組合物或請求項5至8任意一項製備方法所獲得的中藥組合物。
- 請求項1-4任意一項所述的中藥組合物或請求項9所述的中藥製劑在製備治療乳腺癌合併心身症狀的藥物中的應用。
- 根據請求項10所述的應用,所述乳腺癌合併心身症狀為焦慮、抑鬱、失眠、乏力或認知功能下降。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211413178.XA CN115837065B (zh) | 2022-11-11 | 2022-11-11 | 一种中药组合物及其用途 |
CN202211413178X | 2022-11-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202406564A TW202406564A (zh) | 2024-02-16 |
TWI840312B true TWI840312B (zh) | 2024-04-21 |
Family
ID=85575561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112143210A TWI840312B (zh) | 2022-11-11 | 2023-11-09 | 一種中藥組合物及其用途 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN115837065B (zh) |
TW (1) | TWI840312B (zh) |
WO (1) | WO2024099339A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115837065B (zh) * | 2022-11-11 | 2023-11-03 | 北京中医药大学第三附属医院 | 一种中药组合物及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101152330A (zh) * | 2007-09-17 | 2008-04-02 | 尹克华 | 治疗癔病发作的中药 |
CN105362853A (zh) * | 2014-08-25 | 2016-03-02 | 天津市宁河县鑫瑞畜牧养殖场 | 猪蓝耳病的治疗药方 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115837065B (zh) * | 2022-11-11 | 2023-11-03 | 北京中医药大学第三附属医院 | 一种中药组合物及其用途 |
-
2022
- 2022-11-11 CN CN202211413178.XA patent/CN115837065B/zh active Active
-
2023
- 2023-11-08 WO PCT/CN2023/130374 patent/WO2024099339A1/zh unknown
- 2023-11-09 TW TW112143210A patent/TWI840312B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101152330A (zh) * | 2007-09-17 | 2008-04-02 | 尹克华 | 治疗癔病发作的中药 |
CN105362853A (zh) * | 2014-08-25 | 2016-03-02 | 天津市宁河县鑫瑞畜牧养殖场 | 猪蓝耳病的治疗药方 |
Also Published As
Publication number | Publication date |
---|---|
WO2024099339A1 (zh) | 2024-05-16 |
TW202406564A (zh) | 2024-02-16 |
CN115837065B (zh) | 2023-11-03 |
CN115837065A (zh) | 2023-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102908603B (zh) | 一种治疗乳腺增生的中药 | |
TWI840312B (zh) | 一種中藥組合物及其用途 | |
CN104587298A (zh) | 一种治疗肺痈的中药组合物 | |
CN104491695A (zh) | 一种治疗黄褐斑的药物组合物 | |
CN101664536B (zh) | 一种抗肿瘤的中药组合物 | |
CN111388618B (zh) | 一种治疗过敏体质鼻炎及其伴随症的中药膏方及其制备方法 | |
CN101422558B (zh) | 一种治疗梅核气的中药 | |
CN103055266B (zh) | 一种治疗肝癌的中药组合物及其制备方法 | |
CN101209334B (zh) | 一种治疗肺癌的药物及其制备方法 | |
CN106138668A (zh) | 一种治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN102526189B (zh) | 一种治疗冠心病心绞痛的中药组合物 | |
CN104436048A (zh) | 一种中药制剂在制备治疗气滞血瘀型黄褐斑药物中的用途 | |
CN115252753A (zh) | 治疗失眠的中药组合物及其应用 | |
CN115252691A (zh) | 一种用于治疗气滞血瘀型冠心病心绞痛的中药组合物 | |
CN103495022B (zh) | 一种辅助治疗艾滋病的中药 | |
CN105853930A (zh) | 一种治疗抑郁症的中药组合物 | |
CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
CN105617335A (zh) | 改善癌症放化疗后胆汁反流性胃炎的柴胡陷胸汤 | |
CN105535839A (zh) | 一种治疗结肠癌的中药片剂及其制备方法 | |
CN104491316B (zh) | 一种治疗中气不足型前列腺增生症的中药制剂 | |
CN109908294B (zh) | 一种用于治疗支气管扩张症稳定期的药物组合物及其制备方法和用途 | |
CN116211974B (zh) | 一种改善人体微循环的中药组合物 | |
CN114344378B (zh) | 一种治疗血虚瘀阻型颈椎病的中药组合物、制剂与应用 | |
CN113827668B (zh) | 一种治疗退行性膝关节炎的中药复方制剂及其制备方法 | |
CN109602865B (zh) | 一种用于治疗抑郁症的中药组合物及其药物组合和用途 |